BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21350947)

  • 1. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
    Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis.
    Kamai T; Yanai Y; Arai K; Abe H; Yamanishi T; Kurimoto M; Yoshida K
    BMC Cancer; 2007 Aug; 7():159. PubMed ID: 17697365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
    Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
    Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.
    Betsunoh H; Fukuda T; Anzai N; Nishihara D; Mizuno T; Yuki H; Masuda A; Yamaguchi Y; Abe H; Yashi M; Fukabori Y; Yoshida K; Kamai T
    BMC Cancer; 2013 Oct; 13():509. PubMed ID: 24168110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
    Niwakawa M; Hashine K; Yamaguchi R; Fujii H; Hamamoto Y; Fukino K; Tanigawa T; Sumiyoshi Y
    Invest New Drugs; 2012 Jun; 30(3):1046-54. PubMed ID: 21246251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
    Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
    BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
    Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
    Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
    Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
    Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Zołnierek J; Nurzyński P; Langiewicz P; Oborska S; Waśko-Grabowska A; Kuszatal E; Obrocka B; Szczylik C
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):371-8. PubMed ID: 19711099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
    Reddy GK; Bukowski RM
    Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
    J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
    Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
    Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.